Core Viewpoint - Abbott reported Q4 2025 revenue of $11.46 billion, a year-over-year increase of 4.4%, but below analyst expectations of $11.8 billion, primarily due to a sharp decline in COVID-19 testing demand and the impact of the Trump administration's freeze on foreign aid [1] Group 1: Financial Performance - Total revenue for Q4 2025 was $11.46 billion, reflecting a 4.4% year-over-year growth [1] - Adjusted earnings per share (EPS) were $1.50, representing a 12% increase compared to the previous year [1] Group 2: Future Outlook - For 2026, Abbott anticipates organic sales growth of 6.5% to 7.5% [1] - Adjusted EPS for 2026 is projected to be between $5.55 and $5.80 [1]